Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Clin Microbiol Infect Dis ; 24(7): 484-7, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15995845

ABSTRACT

The aim of this study was to assess the diagnostic value of procalcitonin (PCT) in 212 children with appendicitis and compare it with that of the standard diagnostic modalities, C-reactive protein (CRP) level, leukocyte count, and abdominal ultrasound findings, in relation to the surgical and histological findings of the appendix. A PCT value of >0.5 ng/ml was found to be indicative of perforation or gangrene with 73.4% sensitivity and 94.6% specificity, a CRP level of >50 mg/l and a leukocyte count of >10(4)/mm3 were useful diagnostic markers for perforation, while abdominal ultrasonography had a sensitivity of 82.8% and a specificity of 91.2% for detecting appendicitis with imaging findings. PCT measurement seems to be a useful adjunctive tool for diagnosing acute necrotizing appendicitis or perforation, and surgical exploration will probably be required in patients with PCT values >0.5 ng/ml.


Subject(s)
Appendicitis/blood , Appendicitis/diagnosis , Calcitonin/blood , Protein Precursors/blood , Biomarkers/blood , C-Reactive Protein , Calcitonin Gene-Related Peptide , Child , Female , Humans , Leukocyte Count , Male , Sensitivity and Specificity
2.
Int J Antimicrob Agents ; 25(1): 26-30, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15620822

ABSTRACT

Pentavalent antimony compounds and amphotericin B lipid formulations have been found highly active for the treatment of visceral leishmaniasis. This study focuses on which treatment is preferable in the best interests of the child. Records were reviewed of children in our hospital aged 0-14 years, diagnosed with visceral leishmaniasis, during the last 4 years. Twenty-nine children were identified. Ten were treated with meglumine antimonate (20 mg/kg/day for 21 days) and remained in hospital for 11-28 days (median 19 days), while 19 patients received liposomal amphotericin B at four different dosage schemes and were in hospital for 6-11 days (median 7 days). All of the patients were cured regardless of the treatment regime they followed. No relapses were noted. Liposomal amphotericin B would be preferable to meglumine antimonate if the reduction in hospital stay and hence the convenience of the patient balance the cost of medication. The optimal duration of treatment with liposomal amphotericin B remains to be determined.


Subject(s)
Amphotericin B/therapeutic use , Antiprotozoal Agents/therapeutic use , Leishmaniasis, Visceral/drug therapy , Meglumine/therapeutic use , Organometallic Compounds/therapeutic use , Adolescent , Animals , Antimony , Child , Child, Preschool , Female , Greece , Humans , Infant , Infant, Newborn , Leishmania infantum/drug effects , Liposomes , Male , Meglumine Antimoniate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...